Non-Small-Cell Lung Cancer European Survey

Poster presentation during ESMO 2012

The Young Oncologists Committee (YOC) is proud to announce that the NSCLC survey was selected for poster presentation during the ESMO 2012 Congress in Vienna, based on the abstract submitted by Raffaele Califano on behalf of the YOC.

The poster (1183P) was presented during Poster session II, which was held on Sunday 30 September 2012. Download the poster here.

Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small-Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee

NSCLC poster presentation during ESMO 2012

Raffaele Califano presents the NSCLC poster at ESMO 2012 on behalf of the Young Oncologists Committee

This work represents a true international effort and provides considerable insight in to the use of adjuvant treatments for incompletely resected (R1) early stage NSCLC, across Europe. Despite very limited evidence to guide management of this clinical scenario, these treatments are widely used in clinical practice.

This survey sheds light on how this clinical challenge is approached by European oncologists treating lung cancer, and is, to our knowledge, the largest survey ever conducted so far, retrieving 768 responses across 41 European countries.

In order to identify factors influencing treatment decisions, data collected included detailed demographics (i.e. country, specialty (medical vs. radiation oncology), gender, ESMO membership, type of institution, years of clinical practice, research activity, workload and use of ESMO guidelines) and several outcomes such as clinical stage, chemotherapy and radiotherapy regimens used, planned number of cycles of chemotherapy, radiotherapy site, multidisciplinary management and discussion about inconclusive evidence with the patient.

Data has been analysed using a logistic regression model to detect statistical association and to estimate Odds Ratio; the Cochrane-Armitage test was used to detect trends among the outcomes and different demographic sub groups.

Acknowledgments

The YOC is very grateful to Dr Luca Porcu and Dr Valter Torri of the ‘Istituto di Ricerche Farmacologiche "Mario Negri"’ in Milan for the statistical analysis.
The YOC would also like to thank everyone who completed the questionnaire and thus made this study possible.

A very special thank you is extended to all the individuals and organisations who helped to circulate the survey across Europe: ESMO National Representatives, Members of the YOC, Manchester Lung Cancer Group, British Thoracic Oncology Group, The European Thoracic Oncology Platform (ETOP) network (President: Prof. Rolf Stahel), International Congress on Anti-Cancer Treatment (ICACT) 2012, the ESMO Chest Tumor faculty members, European regents of International Association for the Study of Lung Cancer (IASLC), European Cancer Organisation (ECCO) Lung Cancer subgroup and national young oncologist groups in Europe.